search

Benjamin Lewing, PhD

Senior Manager, Health Economics and Outcomes Research

A man with straight brown hair smiles at the camera. He is wearing a checkered shirt and stands in front of a blurry background with blue and white colors.

Benjamin serves as a research consultant within Inovalon’s Data Solutions team, and provides support for health economics and outcomes research projects. Benjamin is experienced in designing observational studies and retrospective database analyses. Prior to joining Inovalon, he held internships at Genentech, as part of their Evidence for Access team, and at Royal Dutch Shell, as part of their Health Risk Science team.

Benjamin has authored/co-authored numerous manuscripts published in peer-reviewed journals, including American Journal of Managed Care, Journal of Opioid Management, and Diabetes Epidemiology and Management. He has also presented scholarly work at numerous scientific conferences and received research awards from International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Benjamin received a PhD in pharmaceutical health outcomes and policy from University of Houston, where his dissertation examined the impact of inadequate care on health outcomes during management of type 2 diabetes, and the role of patient and health system factors in inadequate diabetes care. In addition to his PhD, Benjamin also holds a MA in applied economics from University of Houston, a MS in chemistry from Mississippi College, and a BS in biochemistry from Mississippi College.

Connect on LinkedIn
Authored Content
Placeholder

Gaps in Care Among Uncontrolled Severe Asthma Patients in the United States

Study using Inovalon and Medicare FFS data finds major care gaps, racial disparities in specialist follow-up for uncontrolled severe asthma.

Read More →
Placeholder

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study

This study assess the benefits of prompt administration of budesonide/glycopyrrolate/formoterol fumarate (BGF) following a COPD exacerbation.

Read More →
Placeholder
Respiratory

Treatment Patterns Among Patients with Bronchiectasis by Baseline Exacerbations 6th World Bronchiectasis & Non-Tuberculous Mycobacteria (NTM) Conference. New York, NY.

Management of bronchiectasis relies on treatment of exacerbations. A retrospective observational administrative claims database study (2014-2020) assessed treatment patterns in...

Placeholder
Respiratory

Survival Outcomes in US Medicare Patients With Bronchiectasis by Rate of Baseline Exacerbations 6th World Bronchiectasis & Non-Tuberculous Mycobacteria (NTM) Conference. New York, NY.

Frequent bronchiectasis exacerbations worsen lung function and increase mortality. A retrospective observational administrative claims database study (2014-2020) assessed exacerbation rate...

Placeholder
Respiratory

Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

CD19-directed autologous chimeric Antigen Receptor (CAR) T-cell immunotherapy offers a treatment option to the elderly with relapsed/refractory diffuse large B-cell...

Read More →
Placeholder
Respiratory

Exacerbations and Real-World Outcomes (EROS) Among Patients Diagnosed with COPD Receiving Single Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate to prevent chronic obstructive pulmonary disease exacerbations has been shown to be more efficacious than...

Read More →
Share